MedTrace Logo

A Study of QLM2011 in Subjects With Advanced Solid Tumors

NCT06925659 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2025-04-17

No results posted yet for this study

Summary

This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

QLM2011

QLM2011l by intravenous infusion.

DRUG

Taxotere®

Taxotere® by intravenous infusion

Sponsors & Collaborators

  • Qilu Pharmaceutical (Hainan) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2026-06-30
Completion
2027-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06925659 on ClinicalTrials.gov